(Q36730313)

English

Prediction of survival benefits from progression-free survival benefits in advanced non-small-cell lung cancer: evidence from a meta-analysis of 2334 patients from 5 randomised trials

scientific article published on 13 March 2013

In more languages

default values for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

Prediction of survival benefits from progression-free survival benefits in advanced non-small-cell lung cancer: evidence from a meta-analysis of 2334 patients from 5 randomised trials (English)

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

11

object named as

Marc Buyse

0 references

Emmanuel Quinaux

10

object named as

Emmanuel Quinaux

0 references

Jean-Yves Douillard

7

object named as

Jean-Yves Douillard

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

Frank V Fossella

4

object named as

Frank Fossella

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

3

object named as

Noémie Baroux

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

author name string

Silvy Laporte

1

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

Pierre Squifflet

2

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

Vassilis Georgoulias

5

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

Jean-Louis Pujol

6

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

Shinzohy Kudoh

8

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

Jean-Pierre Pignon

9

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

publication date

13 March 2013

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

3

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

3

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

Blinded independent central review of progression in cancer clinical trials: results from a meta-analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3612819

30 September 2017

Should progression-free survival be the primary measure of efficacy for advanced NSCLC therapy?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3612819

30 September 2017

Detecting an overall survival benefit that is derived from progression-free survival

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3612819

30 September 2017

Duration of chemotherapy for advanced non-small-cell lung cancer: a systematic review and meta-analysis of randomized trials.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3612819

30 September 2017

Individual- and trial-level surrogacy in colorectal cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3612819

30 September 2017

Two simple approaches for validating a binary surrogate endpoint using data from multiple trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3612819

30 September 2017

Comparison of docetaxel- and vinca alkaloid-based chemotherapy in the first-line treatment of advanced non-small cell lung cancer: a meta-analysis of seven randomized clinical trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3612819

30 September 2017

Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3612819

30 September 2017

Progression-free survival is a surrogate for survival in advanced colorectal cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3612819

28 June 2018

Evaluation of tumor response, disease control, progression-free survival, and time to progression as potential surrogate end points in metastatic breast cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3612819

5 September 2018

Surrogate endpoints for overall survival in early colorectal cancer from the clinician's perspective

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3612819

5 September 2018

Practical issues arising in an exploratory analysis evaluating progression-free survival as a surrogate endpoint for overall survival in advanced colorectal cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3612819

5 September 2018

Surrogate endpoint validation: statistical elegance versus clinical relevance.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3612819

5 September 2018

Gemcitabine-docetaxel versus cisplatin-vinorelbine in advanced or metastatic non-small-cell lung cancer: a phase III study addressing the case for cisplatin.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3612819

5 September 2018

Vinorelbine plus cisplatin versus docetaxel plus gemcitabine in advanced non-small-cell lung cancer: a phase III randomized trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3612819

5 September 2018

Efficacy of gemcitabine plus platinum chemotherapy compared with other platinum containing regimens in advanced non-small-cell lung cancer: a meta-analysis of survival outcomes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3612819

5 September 2018

Sequential two-line strategy for stage IV non-small-cell lung cancer: docetaxel-cisplatin versus vinorelbine-cisplatin followed by cross-over to single-agent docetaxel or vinorelbine at progression: final results of a randomised phase II study.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3612819

5 September 2018

Phase III randomized trial of docetaxel plus cisplatin versus vindesine plus cisplatin in patients with stage IV non-small-cell lung cancer: the Japanese Taxotere Lung Cancer Study Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3612819

5 September 2018

Use of progression-free survival as a surrogate marker in oncology trials: some regulatory issues

1 reference

https://pubmed.ncbi.nlm.nih.gov/23485717

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Surrogate endpoints for overall survival in advanced colorectal cancer: a clinician's perspective

1 reference

https://pubmed.ncbi.nlm.nih.gov/23485717

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase III study of docetaxel compared with vinorelbine in elderly patients with advanced non-small-cell lung cancer: results of the West Japan Thoracic Oncology Group Trial (WJTOG 9904)

1 reference

https://pubmed.ncbi.nlm.nih.gov/23485717

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Surrogate endpoints: wishful thinking or reality?

1 reference

https://pubmed.ncbi.nlm.nih.gov/23485717

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Response rate or time to progression as predictors of survival in trials of metastatic colorectal cancer or non-small-cell lung cancer: a meta-analysis

1 reference

https://pubmed.ncbi.nlm.nih.gov/23485717

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Evaluating time to cancer recurrence as a surrogate marker for survival from an information theory perspective

1 reference

https://pubmed.ncbi.nlm.nih.gov/23485717

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Surrogate threshold effect: an alternative measure for meta-analytic surrogate endpoint validation

1 reference

https://pubmed.ncbi.nlm.nih.gov/23485717

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1136/BMJOPEN-2012-001802

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36730313&oldid=1905837752"